Research Reports

Prepared Highlights

Revenue: Q2 2025 revenue of $271M, up 15% YoY (prepared).
Revenue breakdown: Subscription revenue $131M (+17% YoY, +5% sequential); volume-based revenue $138M (+14% YoY, +6% sequential) (CFO).
Adjusted EBITDA: $113M, up 20% YoY; margin 42%, above long-term ~40% target (CFO).
Unlevered free cash flow: $111M in Q2 2025; conversion ratio to adjusted EBITDA of 98% (benefits from delayed federal tax payments) (CFO).
Net leverage: 2.2x net debt to adjusted EBITDA at June 30, down 0.6x since beginning of year (CFO).
Net revenue retention rate: 115% for trailing 12 months (CFO).
Client metrics: 1,268 clients generating >$100k in trailing 12-month revenue, up 14% YoY and +24 clients in Q2 (CEO).
Iodine Software acquisition: Purchase price $1.25B; high teens EV/adjusted EBITDA multiple based on Iodine’s estimated 2025 EBITDA adjusted for synergies; expected to close by year-end (CEO). Iodine stand-alone 2025 revenue ~$120–125M subscription, ~75% gross margin, ~40% adjusted EBITDA margin; >$15M cost synergies within 2 years of close (CFO).
Medicaid exposure: Hypo analysis: 15% Medicaid funding reduction would impact Waystar trailing 12-month revenue by <1% (CEO).
AI/automation: >90% touchless authorizations; prevents nearly $6B in denied claims in H1 2025; 70% boost in appeal productivity from Waystar AltitudeAI (CEO).
Official guidance (FY 2025, excluding Iodine):
- Revenue: $1.30B–$1.42B (midpoint $1.36B, +10% YoY); midpoint increased $22M vs prior guidance.
- Adjusted EBITDA: $418M–$426M (midpoint $422M); margin ~41% for 2025.
- Expect Q3 revenue down sequentially vs Q2; Q3 and Q4 revenue to be similar on absolute dollar basis.
CEO quotes:
- “The acquisition of Iodine is a major step forward in accelerating Waystar's mission to simplify health care payments.” (CEO)
- “We believe Waystar is well insulated from downside risk across a range of scenarios.” (CEO)
- “Waystar delivers more than 90% touchless authorizations.” (CEO)
- “Our AI-powered software platform prevented nearly $6 billion in denied claims in the first half of 2025.” (CEO)
CFO quote:
- “Our adjusted EBITDA margin was 42%, above our long-term target of approximately 40%.” (CFO)

Prepared Metrics

Metric	Value	Speaker/Context
Revenue	$271M (+15% YoY)	CFO
Subscription revenue	$131M (+17% YoY)	CFO
Volume-based revenue	$138M (+14% YoY)	CFO
Adjusted EBITDA	$113M (+20% YoY); margin 42%	CFO
Unlevered FCF	$111M; 98% conversion ratio	CFO
Net debt/adjusted EBITDA leverage	2.2x (down 0.6x YTD)	CFO
Net revenue retention rate	115%	CFO
Clients >$100k revenue	1,268 (+14% YoY)	CEO
Iodine acquisition price	$1.25B	CEO
Iodine 2025 revenue (stand-alone)	~$120–125M subscription	CFO
Iodine gross margin (stand-alone)	~75%	CFO
Iodine adj. EBITDA margin (stand-alone)	~40%	CFO
Cost synergies from Iodine	>$15M within 2 years	CFO
FY 2025 revenue guidance midpoint	$1.36B (+10% YoY)	CFO
FY 2025 adj. EBITDA guidance midpoint	$422M (margin ~41%)	CFO

Q&A Batch (1-5 of 14)

Q1 — Destiny (on behalf of Alexei)

Topic: 客户迁移带来的1000万美元收入一次性影响是否已消退
Key points:
- 1Q25曾提及约1000万美元的客户迁移收入提振，到2Q25该同比影响已完全“拉平”，不再显著影响增长率。
- 原始迁移客户群保持良好留存率，并持续出现交叉销售机会。
- 一项近期调查显示，超过36%的受访者可能更换清算所供应商，其中尚未切换的客户约占三分之一。
Mgmt stance: 看好；认为Waystar在客户切换浪潮中具备竞争优势，有望获得更多市场份额。

Q2 — Adam R. Hotchkiss

Topic: 快速上线大客户的收入是否在下半年具有重复性，以及下半年指引隐含的环比下降原因
Key points:
- Q2同比增速中约2%来自3个快速上线的大客户；约一半收入为订阅软件，另一半为成交量收入，客户合约结构导致订阅部分会在签约后几个月才体现。
- 下半年收入通常低于上半年，原因是约30%收入来自患者付款，而患者自付额在年初重置，下半年开始达标。
- 如果患者

Q&A Batch (6-10 of 14)

Q6 — Elizabeth Hammell Anderson

Topic: 假设的15% Medicaid资金削减对Waystar收入的影响
Key points:
- Waystar平台服务所有支付者类型，业务高度多元化，对单一资金来源具有绝缘性。
- 若Medicaid资金削减15%，其他解决方案（保险覆盖检测、自动资格验证、慈善筛查、AI支付意愿等）需求将上升，作为抵消效应。
- 管理层基于过去12个月数据测算，该场景对Waystar收入影响不足1%。
Mgmt stance: bullish — 分析显示业务韧性，且存在额外收入抵消机会。

Q7 — 未识别分析师

Topic: 健康保险交易所补贴（APTCs）到期对业务的影响
Key points:
- 管理层已进行敏感性分析，认为业务同样因客户与患者多样性而具备绝缘性。
- 未提供具体量化数据，仅强调业务模式强劲、解决方案需求旺盛。
Mgmt stance: bullish — 依赖多元化模型抵御潜在补贴到期风险。

Q8 — Brian Christopher Peterson

Topic: 中周期（Mid-cycle）市场机会与Iodine收购的AI影响
Key points:
- 中周期是提供商痛点最集中的环节，传统上依赖大量人工；Iodine拥有160多个领先定制AI模型，可减少超70%的人工索赔复审工作。
- Iodine每年处理1.6亿次临床接触，覆盖约34%的美国住院患者出院；该收购使Waystar总可寻址市场（TAM）扩大约15%。
- 约1/3的Iodine现有客户也是Waystar客户，形成双向交叉销售机会；客户反馈100%正面。
Mgmt stance: bullish — 收购战略契合AI驱动转型，临床数据将强化现有产品，长期财务回报可期。

Q9 — Ryan Scott Daniels

Topic: 竞争环境与Win rates
Key points:
- 管理层观察到客户持续转向（switching），赢得率保持稳定，与S-1招股书披露水平一致。
- 合格管道（qualified pipeline）中RFP数量和“跳球”机会持续强劲，上半年预订量表现积极。
- 认为Waystar有望成为市场份额获得者（share gainer）。
Mgmt stance: bullish — 竞争态势有利，管道活力强。

Q10 — Jailendra P. Singh

Topic: 健康计划减少事先授权（prior authorization）的承诺及其影响
Key points:
- 目前每年发生超过20亿次事先授权；Waystar现有解决方案已自动化90%的授权流程。
- 管理层认为趋势不是减少需求，而是通过现代API实现实时简化；早期反馈显示提供商和患者对手动授权延迟感到痛苦。
- 简化流程可能减少延迟，但Waystar的否认管理和自动化授权解决方案仍具市场需求。
Mgmt stance: bullish — 认为Waystar可作为市场领导者代表提供商和患者，持续获益于流程优化。

Q&A Batch (11–14 of 14)

Q11 — Lucas (for Charles)

Topic: Competitor cyber attack fallout – retention risk from competitor win-back efforts
Key points:
- Waystar has not noticed competitor reaching out to customers who left after the outage.
- Retention among the cohort that joined Waystar has been “excellent”.
- A survey found that >36% of respondents are looking or likely to switch vendors, and 1/3 of those respondents come from the competitor mentioned.
Mgmt stance: Neutral – no direct threat observed, but opportunity seen in “unrest” among potential clients; mgmt refrained from further comment on competitor actions.

Q12 — Daniel R. Grosslight

Topic: Large client wins – whether guidance accounted for them and details on client type
Key points:
- Question asks if the 3 large client wins that boosted volume revenue were contemplated in Q1 2025 guidance, or if upside came from faster-than-anticipated onboarding.
- Request for detail: competitive takeaways, health system vs. ambulatory, and cross-sell opportunity this year.
Mgmt stance: (Answer deferred to next exchange) – Steven Oreskovich began but did not complete response in this Q&A.

Q13 — Daniel R. Grosslight

Topic: Confirmation of competitive nature of the 3 large client wins
Key points:
- Direct question: “Are these competitive takeaways?”
- Answer: “Yes, yes. They were. In all 3 cases.”
Mgmt stance: Bullish – all three wins were competitive takeaways, underscoring market share gain.

Q14 — Steven James Valiquette (Mizuho)

Topic: Independence from payer-owned competitors resonating with providers
Key points:
- Waystar hears feedback that providers want fairness and a “referee” – concern about conflict if clearinghouse is owned by a payer.
- That “independence” message is resonating “even stronger in 2025”.
- As a public company, Waystar can more effectively share the fairness message; it delivers “hundreds and hundreds” of feature improvements and new capabilities each quarter.
Mgmt stance: Bullish – independence and AI-driven transparency/accuracy are key differentiators; providers see Waystar as future-proofing their revenue cycle, and the message is gaining traction.